ACAD ACADIA Pharmaceuticals Inc.

30.37
-0.65  -2.1%
Previous Close 31.02
Open 31.02
Price To book 6.50
Market Cap 3.68B
Shares 121,113,000
Volume 1,319,841
Short Ratio 8.34
Av. Daily Volume 2,645,920

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 17505014
  2. CT ORDER - Confidential treatment order 162065839
  3. 8-K - Current report 162060264
  4. 8-K - Current report 162056939
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161978343

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated November 2016.
Pimavanserin
Adjunctive treatment in patients with negative symptoms of schizophrenia
Phase 3 initiated November 2016.
Pimavanserin
Adjunctive treatment of schizophrenia
Phase 2 trial initiated October 2016.
Pimavanserin - SERENE
Alzheimer’s disease agitation
Approved April 29 2016
Pimavanserin
Parkinson’s disease psychosis (PDP)
Phase 2 top-line data released December 20, 2016. Primary endpoint met. Key secondary endpoint missed.
Pimavanserin
Alzheimer’s disease psychosis

Latest News

  1. Top Biotech Stocks to Buy in 2017
  2. Why Acadia Pharmaceuticals Inc. Stock Slipped 19% in 2016
  3. Top Stocks to Buy in 2017
  4. 3 Companies Whose Sales Could Double in 2017
  5. Acadia Pharmaceuticals' Alzheimer's Data Raises Some Questions
  6. 3 ideas to improve waiting for your trades
  7. #1 issue top traders want to fix in 2017 on our prop desk
  8. The Market In 5 Minutes: Jobless Claims Fall Again, Retailers Struggle
  9. Why Encana, Acadia Pharmaceuticals, and Tenet Healthcare Jumped Today
  10. Here's Why Acadia Pharmaceuticals Inc. Stock Is Up Today
  11. Biotech Stocks to Watch in 2017 ACADIA Pharmaceuticals and Exelixis
  12. ACADIA Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 10, 2017
  13. Vetr Still Bullish On Acadia Despite Downgrade
  14. 4 Biotech Stocks to Buy in January
  15. 3 Companies Whose Revenue Could Double in 2017
  16. ACADIA Phase II Alzheimer's Drug Hits Primary Endpoint
  17. Today's Reports on Biotech Movers ACADIA Pharmaceuticals and Conatus Pharmaceuticals
  18. Acadia Jumps Following Phase II Alzheimer's Study
  19. Why ACADIA Pharmaceuticals Inc. Is Soaring Today
  20. Tesla Motors Inc (TSLA), Netflix, ACADIA Pharmaceuticals: This Hedge Fund Manager’s Top Stock Picks for 2017

SEC Filings

  1. CT ORDER - Confidential treatment order 17505014
  2. CT ORDER - Confidential treatment order 162065839
  3. 8-K - Current report 162060264
  4. 8-K - Current report 162056939
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161978343
  6. 8-K - Current report 161978236
  7. CT ORDER - Confidential treatment order 161898391
  8. 8-K - Current report 161849527
  9. S-8 - Securities to be offered to employees in employee benefit plans 161828971
  10. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 161828447